Roche's Divarasib: A New Standard of Care Emerges to Challenge Amgen's KRAS Dominance

Related Articles

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

3 months ago

Together AI's $8.3 Billion Valuation: A Neocloud's Challenge to Hyperscaler AI Dominance

4 months ago

What's Driving Amgen's Recent Volatility

5 months ago

Has Accel Entertainment's Recent Performance Set a New Standard

8 months ago

Category

You may also like

Stock News•3 weeks ago

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem presented updated VS-7375 data showing pancreatic responses in the TARGET-D 101 study and outlined plans for registrational Phase II and frontline Phase III trials. The oral KRAS G12D inhibit...

VSTM

Share

Stock News•2 months ago

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Akeso's ivonescimab met the overall survival key secondary endpoint in an interim analysis of the Phase III HARMONi-2 study, showing a statistically significant and clinically meaningful benefit versu...

9926.HK

Share

Stock News•2 months ago

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor for metastatic pancreatic cancer, positioning it as a potential blockbuster. Despite a $3.9...

RVMD

Share